| Literature DB >> 33870245 |
Hannah Taylor1,2, William Wall2, David Ross2, Roshni Janarthanan3, Liyang Wang3, Felicity Aiano1, Joanna Ellis4, Robin Gopal4, Nick Andrews5, Monika Patel4, Angie Lackenby4, Richard Myers5, Mary E Ramsay1, J Yimmy Chow3, Maria Zambon4, Shamez N Ladhani1,6.
Abstract
BACKGROUND: Military personnel in enclosed societies are at increased risk of respiratory infections. We investigated an outbreak of Coronavirus Disease 2019 in a London Army barracks early in the pandemic.Entities:
Year: 2021 PMID: 33870245 PMCID: PMC7834392 DOI: 10.1016/j.lanepe.2020.100015
Source DB: PubMed Journal: Lancet Reg Health Eur ISSN: 2666-7762
Fig. 1SARS-CoV-2 antibody positivity by RT-PCR status at visit 1 in participants COVID-19 outbreak investigation in a London Army barracks.
Key demographics of 304 participant at visit 1.
| Demographics of 304 Participants | ||
|---|---|---|
| Age | n= | 302 |
| Median | IQR | Range |
| 28 years | 23-36 years | 18-57 years |
| Gender (n=304) | ||
| Count (Rate) | ||
| Male | 247 (81%) | |
| Female | 57 (19%) | |
| Status (n=300) | ||
| Army | 254 (85%) | |
| Civilian | 36 (12%) | |
| Family | 10 (3%) | |
| Share Bedroom (n=296) | ||
| No | 167 (56%) | |
| Yes | 129 (44%) | |
| Share Bathroom (n=303) | ||
| No | 273 (90%) | |
| Yes | 30 (10%) | |
| COVID-19 close contact (n=303) | ||
| No | 283 (93%) | |
| Yes | 20 (7%) | |
| Smoke or Vape (n=43) | ||
| No | 34 (79%) | |
| Yes | 9 (21% | |
| Symptoms (n=304) | ||
| Count if Yes to Symptom (Rate) | ||
| Fever | 27 (9%) | |
| Cough | 46 (37%) | |
| Anosmia | 7 (2%) | |
| Ageusia | 6 (2%) | |
Further details are contained in Supplement Table S2.
Fig. 2Changes in IgG and Neutralising antibody levels on a log scale with lines of equivalence.
Fig. 3Venn diagrams showing interaction of RT-PCR results and serology outcomes of participants during a COVID-19 outbreak investigation in a London Army barracks.
Fig. 4Epidemiological curve of possible and confirmed cases during a COVID-19 outbreak investigation in a London Army barracks.
Factors associated with SARS-CoV-2 RT-PCR positivity in Visit 1 during a COVID-19 outbreak investigation in a London Army barracks.
| Demographic variable | PCR-positivity (Visit 1) | ||
|---|---|---|---|
| Risk | RR (95% CI) | Risk Difference (95% CI) | |
| Female | 7/57 (12%) | 1.8 (0.8 to 4.1) | 0.05 (-0.04 to 0.2) |
| Male | 17/245 (7%) | Baseline | |
| Yes | 9/128 (7%) | 0.8 (0.4 to 1.9) | - 0.01 (-0.08 to 0.05) |
| No | 14/166 (8%) | Baseline | |
| Yes | 22/271 (8%) | 1.2 (0.3 to 4.9) | 0.01 (-0.08 to 0.1) |
| No | 2/30 (7%) | Baseline | |
| Yes | 14/115 (12%) | 2.4 (1.1 to 5.4) | 0.07 (0.003 to 0.1) |
| No | 9/179 (5%) | Baseline | |
| Yes | 4/8 (50%) | 7.3 (3.3 to 16.5) | 0.4 (0.08 to 0.8) |
| No | 20/293 (7%) | Baseline | |
| Yes | 1/9 (11%) | 0.2 (0.03 to 1.1) | -0.5 (-0.8 to -0.3) |
| No | 22/34 (65%) | Baseline | |
| Asymptomatic Female | 5/42 (12%) | 1.8 (0.7 to 4.8) | 0.05 (-0.05 to 0.2) |
| Asymptomatic Male | 12/180 (7%) | Baseline | |
| Symptomatic Female | 2/15 (13% | 1.7 (0.4 to 8.1) | 0.06 (-0.1 to 0.2) |
| Symptomatic Male | 5/65 (8%) | Baseline | |
Army/civilian/family status is not included as the results are confounded by the transmission dynamics of the virus through the barracks with civilians most likely to have recent infection and Army personnel previous infection.
Factors associated with SARS-CoV-2 IgG and Neutralising antibody positivity in Visit 1.
| Variable | IgG Antibody positivity (Visit 1) | Neutralising Antibody positivity (Visit 1) | ||||||
|---|---|---|---|---|---|---|---|---|
| Risk | RR (95% CI) | Risk Difference (95% CI) | Risk | RR (95% CI) | Risk Difference (95% CI) | |||
| Female | 7/54 (13%) | 2.5 (1.0 to 6.0) | 0.08 (-0.02 to 0.2) | 9/15 (60%) | 2.2 (1 to 4.7) | 0.3 (0.03 to 0.6) | ||
| Male | 12/231 (5%) | Baseline | 7/26 (27%) | Baseline | ||||
| Yes | 8/119 (7%) | 1.0 (0.4 to 2.3) | -0.002 (-0.06 to 0.06) | 7/14 (50%) | 1.4 (0.7 to 2.9) | 0.1 (-0.2 to 0.5) | ||
| No | 11/159 (7%) | Baseline | 9/25 (36%) | Baseline | ||||
| Yes | 19/257 (8%) | _ | 0.08 (0.04 to 0.1) | 15/36 (42%) | 2 (0.3 to 12.5) | 0.2 (-0.2 to 0.6) | ||
| No | 0/28 (0%) | Baseline | 1/5 (20%) | Baseline | ||||
| Yes | 12/110 (11%) | 2.6 (1.1 to 6.4) | 0.07 (0.002 to 0.1) | 11/22 (50%) | 1.7 (0.7 to 4) | 0.2 (-0.09 to 0.5) | ||
| No | 7/168 (4%) | Baseline | 5/17 (29%) | Baseline | ||||
| Yes | 8/8 (100%) | 25.2 (14.0 to 45.0) | 0.96 (0.9 to 0.98) | 7/8 (88%) | 3.2 (1.7 to 6.0) | 0.6 (0.3 to 0.9) | ||
| No | 11/277 (4%) | Baseline | 9/33 (27%) | Baseline | ||||
| Yes | 3/9 (33%) | 0.7 (0.3 to 1.8) | -0.2 (-0.5 to 0.2) | 0/4 | NA | -0.5 (-0.6 to -0.3) | ||
| No | 16/33 (48%) | Baseline | 13/28 (46%) | Baseline | ||||
| Asymptomatic Female | 6/39 (15%) | 6.5 (1.9 to 22.1) | 0.1 (0.01 to 0.2) | 8/12 (67%) | 3.8 (1.3 to 11.4) | 0.5 (0.2 to 0.8) | ||
| Asymptomatic Male | 4/170 (2%) | Baseline | 3/17 (18%) | Baseline | ||||
| Symptomatic Female | 1/15 (7%) | 0.5 (0.1 to 3.8) | -0.06 (-0.2 to 0.09) | 1/3 (33%) | 0.8 (0.1 to 4.4) | -0.1 (-0.7 to 0.5) | ||
| Symptomatic Male | 8/61 (13%) | Baseline | 4/9 (44%) | Baseline | ||||
Factors associated with SARS-CoV-2 IgG and Neutralising antibody positivity in Visit 2.
| Variable | IgG Antibody positivity (Visit 2) | Neutralising Antibody positivity (Visit 2) | ||||||
|---|---|---|---|---|---|---|---|---|
| Risk | RR (95% CI) | Risk Difference (95% CI) | Risk | RR (95% CI) | Risk Difference (95% CI) | |||
| Female | 5/37 (14%) | 1.1 (0.4 to 2.6) | 0.007 (-0.1 to 0.1) | 2/6 (33%) | 0.7 (0.2 to 2.2) | -0.2 (-0.6 to 0.3) | ||
| Male | 20/156 (13%) | Baseline | 11/22 (50%) | Baseline | ||||
| Yes | 7/87 (8%) | 0.5 (0.2 to 1.0) | -0.09 (-0.2 to -0.003) | 5/8 (63%) | 1.6 (0.7 to 3.3) | 0.23 (-0.2 to 0.6) | ||
| No | 18/102 (18%) | Baseline | 8/20 (40%) | Baseline | ||||
| Yes | 22/172 (13%) | 0.9 (0.3 to 2.7) | -0.01 (-0.2 to 0.1) | 11/24 (46%) | 0.9 (0.3 to 2.7) | -0.04 (-0.6 to 0.5) | ||
| No | 3/21 (14%) | Baseline | 2/4 (50%) | Baseline | ||||
| Yes | 16/72 (22%) | 2.9 (1.3 to 6.2) | 0.2 (0.04 to 0.3) | 8/17 (47%) | 1 (0.5 to 2.4) | 0.02 (-0.4 to 0.4) | ||
| No | 9/117 (8%) | Baseline | 5/11 (45%) | Baseline | ||||
| Yes | 3/8 (38%) | 0.5 (0.2-1.2) | -0.4(-0.8 to -0.1) | 0/3 | NA | -0.7 (-0.9 to -0.5) | ||
| No | 17/21 (81%) | Baseline | 12/17 (71%) | Baseline | ||||
| Asymptomatic Female | 5/29 (17%) | 2.1 (0.8 to 5.7) | 0.1 (-0.6 to 0.2) | 2/6 (33%) | 0.6 (0.2 to 2.1) | -0.2 (-0.7 to 0.3) | ||
| Asymptomatic Male | 9/109 (8%) | Baseline | 6/11 (55%) | Baseline | ||||
| Symptomatic Female | 0/8 (0%) | NA | -0.2 (-0.4 to -0.1) | 0/0 | NA | NA | ||
| Symptomatic Male | 11/47 (23%) | Baseline | 5/11 (45%) | Baseline | ||||
| Yes | 5/5 (100%) | 9.4 (6.2 to 14.2) | 0.9 (0.8 to 0.94) | 3/5 (60%) | 1.4 (0.6 to 3.2) | 0.17 (-0.3 to 0.6) | ||
| No | 20/188 (11%) | Baseline | 10/23 (43%) | Baseline | ||||
Army/civilian/family status is not included as the results are confounded by the transmission dynamics of the virus through the barracks with civilians most likely to have recent infection and Army personnel with previous infection.